Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

News Focus

LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)

Bullboard - Stock Discussion Forum Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s): MEDXF

Healthcare

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its... see more

Add To Watchlist

Bullboard (TSX:MDP)

View:

Post by lscfaon Nov 08, 2024 1:02pm

$100M shelf prospectus filed

On sedar.

(0)
•••

Post by PressReleaseon Jun 18, 2024 5:01pm

New Press Release - Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June 26, 2024 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March...read article.

Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million

posted Nov 21, 2024 9:00am by Innocan Pharma Corp

"Our strong operational and financial momentum continued throughout 2024 and now in the third quarter, we again demonstrated solid financial results. We are pleased to report nine consecutive quarters of continuous revenue growth. Our online platform continues to perform exceptionally well, contributing to our strong nine-month revenue growth of 174% YoY ...read more

(0)
•••

Post by PressReleaseon Jun 06, 2024 10:42am

New Press Release - Canadian Investment Regulatory Organization Trading Halt - MDP

TORONTO, June 6, 2024 /CNW/ - The following issues have been halted by CIRO:Company: Medexus Pharmaceuticals Inc.TSX Symbol: MDPAll Issues: YesReason: Pending NewsHalt Time (ET): 10:03 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed...read article.

(0)
•••

Post by PressReleaseon Jun 06, 2024 10:35am

New Press Release - Canadian Investment Regulatory Organization Trade Resumption - MDP

TORONTO, June 6, 2024 /CNW/ - Trading resumes in:Company: Medexus Pharmaceuticals Inc.TSX Symbol: MDPAll Issues: YesResumption (ET): 11:00 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to...read article.

(0)
•••

Post by PressReleaseon Jun 06, 2024 10:19am

New Press Release - FDA Accepts for Review Treosulfan NDA Resubmission

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 6, 2024) - On Thursday, June 6, 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has accepted for...read article.

Comment by Napcooon May 21, 2024 11:11pm

RE:RE:This article favor Treo over busulfan

Published on May 26, 2022, announced NDA resubmission on July 25, 2022, FDA rejected on September x https://onlinelibrary.wiley.com/doi/10.1002/ajh.26620

Discussion

Comment by Napcooon May 21, 2024 10:47pm

RE:RE:RE:This article favor Treo over busulfan

On treosulfan, we are pleased to report that the data collection phase of medac's effort to respond to the FDA's information requests on treosulfan is now complete," Mr d'Entremont ...more

120

Discussion

Comment by Napcooon May 21, 2024 10:40pm

RE:RE:This article favor Treo over busulfan

An NDA includes all animal and human data and analyses of the data, as well as information about how the drug behaves in the body and how it is manufactured. When an NDA comes in, the FDA has 60 days ...more

Discussion

Comment by Napcooon May 21, 2024 10:26pm

RE:This article favor Treo over busulfan

The second published by nature favor Treo https://www.nature.com/articles/s41409-024-02269-4

Discussion

Post by Napcooon May 21, 2024 10:12pm

This article favor Treo over busulfan

https://www.nature.com/articles/s41409-023-02135-9

138

Discussion

(0)
•••

Post by PressReleaseon Apr 02, 2024 7:31am

New Press Release - Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 2, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that company management will be participating in the 2024 Bloom Burton & Co. Healthcare Investor Conference from April 16 to 17, 2024.Event: 2024...read article.

Comment by Napcooon Mar 29, 2024 9:00pm

RE:Trend Continues

He is just trying to earn a living, there isn't any truth out of him

Discussion

Post by TheMediaon Mar 29, 2024 3:34pm

Trend Continues

March26th Equity Guru/Chris Parry writes up the company. Another company suckered out of their money by this scam out-fit. Stocks do nothing but lose money for anyone following this useless out-fit.

149

Discussion

Comment by Napcooon Mar 28, 2024 6:50pm

RE:RE:Ixinity replacement therapy

Gene therapy needs time to verify the long term results, giving replacement therapy such as ixinity a break https://www.ema.europa.eu/en/news/first-gene-therapy-treat-haemophilia-b

Discussion

Comment by Napcooon Mar 28, 2024 6:40pm

RE:RE:Ixinity replacement therapy

FDA-approved gene therapies In November 2022, the Food and Drug Administration approved Hemgenix, CSL Behring's hemophilia B gene therapy. Researchers at Children’s Hospital of Philadelphia are ...more

Discussion

The Market Update

< Previous bulletin

Next bulletin >

A daily snapshot of everything
from market open to close.

< Previous

Next >

Dealroom for high-potential pre-IPO opportunities

Become a member today, It's free!

Bullboard - Stock Discussion Forum Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s): MEDXF

Bullboard (TSX:MDP)

$100M shelf prospectus filed

New Press Release - Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call

Pharmaceutical Tech Co Reports 2.7X Revenue Growth Year-Over-Year at US $24 Million

New Press Release - Canadian Investment Regulatory Organization Trading Halt - MDP

New Press Release - Canadian Investment Regulatory Organization Trade Resumption - MDP

New Press Release - FDA Accepts for Review Treosulfan NDA Resubmission

RE:RE:This article favor Treo over busulfan

RE:RE:RE:This article favor Treo over busulfan

RE:RE:This article favor Treo over busulfan

RE:This article favor Treo over busulfan

This article favor Treo over busulfan

New Press Release - Medexus to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference

RE:Trend Continues

Trend Continues

RE:RE:Ixinity replacement therapy

RE:RE:Ixinity replacement therapy

Featured News Links

Discover Options Trading Strategies to Minimize your Tax Burden

Become a member today, It's free!

Sign In

Send my password

Become a member today, It's free!

Bullboard - Stock Discussion Forum Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s): MEDXF

Join the community and start posting on the bullboards today. It's free.

Create a portfolio watchlist today. It's free.

Bullboard (TSX:MDP)

Featured News Links